mim

5 P & DOCKET NO: 368-014

PATENT

JAN 3 1 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of Kinam Park, et al.

Serial No: 09/975,800 : Art Unit: Unassigned

Filed: October 11, 2001 : Examiner: Unassigned

For: PHARMACEUTICAL APPLICATIONS: OF HYDROTROPIC AGENTS, POLYMERS: THEREOF, AND HYDROGELS THEREOF:

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the provisions of 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefor.

Inasmuch as the disclosures of U.S. Patent Nos. 4,933,643; 4,981,974; and 5,008,367 (Dandreaux et al.) are cumulative, only the last listed patent is enclosed. Inasmuch as the disclosures of U.S. Patent Nos. 4,946,967 and 4,987,210 (Login et al.) are cumulative, only the latter patent is enclosed. 37 CFR 1.98(c).

U.S. Serial No. 09/975,800

This Information Disclosure Statement is filed within three months of the filing date for this continued prosecution application (CPA) OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

Respectfully submitted,

James H. Meadows, Ph.D.

Reg. No. 33,965

Correspondence Address

5355 Mira Sorrento Pl.

Suite 100

San Diego, CA 92121

Tel: 619-641-8228

Fax: 503-217-9394

Date: January 18, 2002

I, James H. Meadows, hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on 1/19/02 Signature 4 January 19/02 Signature

Plance have a plactic of the land this have	DTO (50 (000 (40 05)
Please type a plus sign (+) inside this box \rightarrow \downarrow	PTO/SB/08B (10-96)
'	Approved for use through 10/31/99. OMB 0651-0031
<u> </u>	Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons	are required to respond to a collection of information unless it
contains a valid OMR control number	·

Substitute for form 1449A/PTO JAN 3 1 2002

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of 3

Complete if Known				
Application Number	09/975,800			
Filing Date	October 11, 2001			
First named Inventor	Kinam Park			
Group Art Unit				
Examiner Name				
Attorney Docket Number	368-014			

			U.S. PATENT DOCUM	1ENTS	
Examiner Initials*	Cite No.1	U.S. Patent Document Kind Number Code2	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages o Relevant Figures Appear
		4,933,463	Dandreaux et al.	6/1990	
		4,981,974	Dandreaux et al.	1/1991	
		5,008,367	Dandreaux et al.	8/1991	
		4,946,967	Login et al.	8/1990	
		4,987,210	Login et al.	1/1991	
		6,248,771	Shenoy et al.	6/2001	
		5,756,450	Hahn et al.	5/1998	
		5,902,606	Wunderlich et al.	5/1999	
	i. 				
		1			

			FORE:	IGN PATENT D	OCUMENTS		
	Foreig	n Patent Doc		Name of Patentee	Date of Publication	Pages, Columns, Lines.	1
Cite No.1	Office3	Number4	Kind Code5	or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
		***		·			T6
	-						
							<u> </u>
_							1
							<u> </u>
							
	 						├—
	Cite No.1	Cite	Cite	Cite Kind	Cite Kind or Applicant of	Cite Kind or Applicant of of Cited Document	Cite Foreign Patent Document Name of Patentee Or Applicant of Of Cited Document Where Relevant Passages

Examiner	Date	
Signature	Considered	
0.3		<u></u>

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box \rightarrow	+
---	---

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it

contains a valid OMB control number.
Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
2 of 3

Complete if Known

Application Number 09/975,800

Filing Date October 11, 2001

First named Inventor Kinam Park

Group Art Unit

Examiner Name

Attorney Docket Number 368-014

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т6
		NICOLAOU, K. et al. "Design, synthesis and biological activity of protaxols," Nature, 1993, 364: 464-466.	
		PENDRI, A., et al. "Antitumor activity of paclitaxel-2'-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug," Anti-Cancer Drug Design, 1998, 13: 387-395.	
		TAVARE, N. et al. "Solubilities of 6-aminopenicillanic acid and phenoxyacetic acid in hydrotrope solutions," J. Chem. Eng. Data, 1996, 41: 1196-1202.	
		MULLER, B. et al. "Effect of hydrotropic substances on the complexation of sparingly soluble drugs with cyclodextrin derivatives and the influence of cyclodextrin complexation on the pharmacokinetics of the drugs," J. Pharm. Sci., 1991, 80: 599-604.	
		GRAZIANO, G. "On the solvent isotope effect in hydrophobic hydration," J. Phys. Chem. B, 2000, 104: 9249-9254.	
		KUMAR, M. et al. "Effect of hydrotropes on solubility and mass transfer coefficient of methyl salicylate," J.Chem.Eng. Data, 2000, 45: 419-423.	
		SRINIVAS. V., et al. "When does the switch from hydrotropy to micellar behavior occur?" Langmuir, 1998, 14: 6658-6661.	
		DHARA, D. et al., "Effect of hydrotropes on the volume phase transition in poly(N-isopropylacrylamide) hydrogel," Langmuir, 1999, 15: 930-935.	
		SALEH, A., et al., "Solubilization of water by hydrotropic salts," J. Pharm.Sci., 1986, 75: 644-647.	
		COFFMAN, R., et al., "Effect of nicotinamide and urea on the solubility of riboflavin in various solvents," J.Pharm.Sci., 1996, 85: 951-954.	
		SERAJUDDIN, A. "Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs," J. Pharm. Sci., 1999, 88: 1058-1066.	
		ALKAN-ONYUKSEL, H. et al. "A mixed micellar formulation suitable for the parenteral administration of taxol," Pharm.Res., 1994, 11: 206-212.	
		SHARMA, A. et al. "Novel taxol formulations: preparation and characterization of taxol-containing liposomes," Pharm. Res., 1994, 11:889-896.	
		MANI, S., et al. "Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)," Cancer Chemother. Pharm., 1998, 42: 84-87.	

Examiner		Date		
Signature	_	Considered	ì	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the contains a	Paperw valid O	s sign (+) inside this box → + ork Reduction Act of 1995, no person MB control number.	Patent and Tradomark Office	PTO/SB/08B (1 se through 10/31/99. OMB 065: ce: U.S. DEPARTMENT OF COMI a collection of information unles	1-003
Substitute	tor torn	n 1449B/PTO		pplete if Known	
TAIF		ATTON BYON A SUR	Application Number	09/975,800	
		ATION DISCLOSURE	Filing Date	October 11, 2001	
ST	ATEM	IENT BY APPLICANT	First named Inventor	Kinam Park	
	use as i	many sheets as necessary)	Group Art Unit		
Sheet 3		of 3	Examiner Name		
Sheet 3			Attorney Docket Number	368-014	
1		OTHER PRIOR ART NON B	TRAIN		
!!/	T	OTHER PRIOR ART-NON PA	ATENT LITERATURE	DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITA (book, magazine, journal, serial, syr publisher	riposium, catalog, etc.), date, pag	le(s), volume-issue number(s),	
· · · · · · · · · · · · · · · · · · ·		69-88.	f solid dispersions," Pharr	m. Acta Helv., 1986, 61:	T6
	ļ	LEUNG, S. et al., "Polymeric n	nicellar paclitavel phosph	orulates hal 2 and induses	├
		apoptotic regression of androge	n-independent LNCaP ne	or yrates oci+2 and induces	1
	ŀ	Prostate, 2000, 44: 156-163.	independent bivear pri	ostate tumors, The	
		CHIOU, W., et al., "Pharmaceu	tical Applications of C. I.	15:	<u> </u>
		Filarin. Sci., 1971, 60: 1281-130	02.		
		FLOYD, A. G. et al. "7. Injecta	ble emulsions and suspen	sions." Pharmaceutical	-
		Dosage Forms: Disperse System	ns. 1998, pp. 261-318, Vo	1 2 Marcel Dekker Inc	
Dosage Forms: Disperse Systems. 1998, pp. 261-318, Vol. 2, Marcel Dekker, Inc.,					

MACHERAS, P., et al., "4. Supply of the gastrointestinal fluids with drug," Biopharmaceutics of Orally Administered Drugs. 1995, pp. 35-87, Ellis Horwood,

LOBENBERG, R., et al., "9. Solubility as a limiting factor to drug absorption," Oral Drug Absorption. Prediction and Assessment, pp. 137-153, Marcel Dekker,

MULLER, R. H. et al., "9. Nanosuspensions," Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs, 1998, pp. 149-174, Medpharm Scientific

HABIB, M. J., et al. "2. Fundamentals of solid dispersions," Pharmaceutical Solid Dispersion Technology, 2001, pp. 7-35, Technomic Pub. Co., Inc., Lancaster, PA MARTIN, A., et al., Physical Pharmacy. Physical Chemical Principles in the Pharmaceutical Sciences, 1993, pp.272-273, 4thed, Lea & Febiger, Philadelphia, PA YALKOWSKY, S., Solubility & Solubilization in Aqueous Media, 1999, p. 429,

					
Examiner Signature *EXAMINER: Initial if reference considered, whether or not citation if not in conformance and not considered. Include copy of	Date Considered on is in conformation of this form with	ance with MPEP 609; Draw line through next communication to applicant.			

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

New York, NY

New York, NY.

Inc., New York, NY

Publ., Stuttgart, Germany

ACS Publ., Washington, DC

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.